Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 6/20 | 0.36 |
| ▸ | MMP13 | P45452 | 5/20 | 0.36 |
| ▸ | MMP14 | P50281 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 4/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5882945 | 0.81 | APLNR (0.32) | APLNR | |
| SCHEMBL272438 | 0.78 | MEN1 (0.30) | — | |
| SCHEMBL12463409 | 0.75 | JAK2 (0.33) | ADAMTS4MMP13MMP14KCNH2CYP3A4 | |
| SCHEMBL18428183 | 0.75 | JAK2 (0.33) | ADAMTS4MMP13MMP14KCNH2CYP3A4 | |
| SCHEMBL20200600 | 0.72 | APLNR (0.41) | ADAMTS4MMP13MMP14KCNH2CYP3A4 | |
| SCHEMBL20190946 | 0.72 | APLNR (0.41) | ADAMTS4MMP13MMP14KCNH2CYP3A4 | |
| SCHEMBL20188961 | 0.72 | APLNR (0.41) | ADAMTS4MMP13MMP14KCNH2CYP3A4 | |
| SCHEMBL24975585 | 0.71 | ESR1 (0.32) | — | |
| SCHEMBL20200794 | 0.71 | ADAMTS4 (0.32) | ADAMTS4MMP13MMP14KCNH2CYP3A4 | |
| SCHEMBL20200614 | 0.71 | ADAMTS4 (0.32) | ADAMTS4MMP13MMP14KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-7122551-B2 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| US-20040176386-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| US-6734183-B2 | USEFUL AS METALLOPROTEINASE INHIBITOR; PIPERAZINO-SULFONAMIDE OR PIPERIDINO-SULFONAMIDE COMPOUND | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | ADAMTS4 25/4885MMP13 1/4885MMP14 12/4885 |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | TIMP3, MMP2, MMP13 | ADAMTS4 28/4885MMP13 3/4885MMP14 11/4885 |
| US-20040176386-A1 | Compounds | MMP13, MMP11, MMP3 | ADAMTS4 25/4885MMP13 1/4885MMP14 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.